NEUROFIBROMATOSIS TYPE 1: REPORT OF TWO CONTRASTING CASES by SHEIKH, N. & MCLIGEYO, S.O.
November 2002 EAST AFRICAN MEDICAL JOURNAL 607
East African Medical Journal Vol. 79 No. 11 November 2002.
NEUROFIBROMATOSIS TYPE 1: REPORT OF TWO CONTRASTING CASES
N. Sheikh, MBChB, Senior House Officer and S.O. McLigeyo, MBChB, MMed, Associate Professor, Department of Medicine, College of Health Sciences,
University of Nairobi, P.O. Box 19676, Nairobi, Kenya.
Request for reprints to: Prof. S.O. McLigeyo, Department of Medicine, College of Health Sciences, University of Nairobi, P.O. Box 19676, Nairobi, Kenya.
NEUROFIBROMATOSIS TYPE 1: REPORT OF TWO CONTRASTING CASES
N. SHEIKH and S.O. MCLIGEYO
SUMMARY
We present two cases of neurofibromatosis type 1(NF-1), one a 35 year old male who
first recognised his problem at the age of fifteen years and at the time of assessment,
satisfied the National Institute of Health (NIH) diagnostic criteria for NF-1 and had
a nodular plexiform neurofibroma involving the left fifth dorsal nerve root and a
diffuse plexiform neurofibroma involving the left lower limb. The second patient, a
45 year old female recognised her problem at the age of 39 years, did not quite satisfy
the NIH diagnostic criteria for NF 1 and had diffuse plexiform neurofibroma involving
both lower limbs and buttocks almost symmetrically, a finding which has not
previously been described to the best of our knowledge. The scarcity of management
options are briefly outlined.
INTRODUCTION
Eight subtypes of neurofibromatosis are currently
recognised, of which NF-1 (classic or Von
Recklinghausen is or peripheral NF) is by far the
commonest(1). Neurofibromatosis type 1 is a familial
autosomal dominant disorder that primarily affects cell
growth of neural tissues. It affects approximately one
in 4000 persons. The genetic disorder lies on
chromosome 17q11.2. In 1990, the NF-1 gene was
cloned and its protein product neurofibromin was
identified. There was a 50% frequency of de-novo
mutation, with a mutation rate of 1 in 10,000(2). NF-
1 is a distinct entity and does not evolve into other
forms of neurofibromatosis.
NF-1 is a progressive genetic disorder with diverse
cutaneous, neurologic, skeletal, and neoplastic
manifestations. The disorder is characterised by cafe-
au-lait macules, intertriginous freckles, neurofibromas,
Lisch nodules, optic gliomas, bony dysplasias, and
learning disabilities. Neurofibromas are tumours of
nerve and fibrous tissue that grow in and along nerves
and nerve sheath. The number, location and size of
tumours vary greatly from individual to individual.
Non-cutaneous tumours of nerve structures may develop
and may interfere with function. Dermal neurofibromas
may occasionally become malignant. There is an
increased risk of other tumours and malignancies
associated with NF-1, including gliomas, neuro-
fibrosarcomas, leukaemia, and pheochromocytomas.
Numerous benign cutaneous or subcutaneous
neurofibromas usually are present in adults with
NF-1. Plexiform neurofibromas are less common but
can cause disfigurement and may compromise function
or even jeopardise life.
The diagnostic criteria for NF-1 developed by an
NIH Consensus Conference in 1987(3) are generally
ccepted, although they are often inadequate for
establishing the presence of NF-1 in small children
without a family history of the disease. The NIH
diagnostic riteria for NF-1 are met in an individual
who has two or more of the following features:
• Six or more cafe-au-lait macules over 5mm in
greatest diameter in prepubertal individuals and
over 15mm in greatest diameter in postpubertal
individuals.
• Two or more neurofibromas of any type or one
pl xiform neurofibroma. Four types of neuro-
fibromas are currently recognised(4) viz:- cutaneous
neurofibromas, subcutaneous neurofibromas,
nodular plexiform neurofibromas and diffuse
plexiform neurofibromas.
• Freckling in the axillary or inguinal regions.
• Optic glioma.
• Two or more Lisch nodules (iris hamaratomas).
• A distinctive osseous lesion such as sphenoid
dys lasia or thinning of long bone cortex with or
without pseudoarthrosis.
• A first-degree relative (parent, sibling or offspring)
with NF-1 by the above criteria.
We report on two contrasting cases of
neurofibromatosis, one of which has not been previously
described, to the best of our knowledge.
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CASE REPORTS
Case 1: N.K., a 35 year old male, presented with an
enlarged left lower limb which had been present since the
age of 15 years. The enlargement had been progressively
increasing in size and over the last six months he had noted
ulcerations on the feet and toes which were not-healing,
despite treatment at several peripheral health units. In
addition, he complained of multiple discolourations on the
trunk and a swelling on the lateral aspect of the chest on
the left. He was unable to walk due to the size of the left
lower limb and the ulcerations. He gave no history of similar
illness in the immediate family members.
On examination, he was in a fair general condition,
afebrile and not pale. He had multiple cafe`au lait spots
varying in size from 0.5cm x 0.7cm to 10cm x 12cm on
the anterior and posterior aspects of the trunk. He had freckles
in both axillae. The left lower limb (Figure 1) was grossly
enlarged as compared to the right and appeared segmented.
He had septic ulcerations on the left sole and beneath the
heads of the left second and third metatarsal bones. On the
lateral aspect of the left side of the chest, just below the
nipple, there was a subcutaneous swelling measuring 12cm
x 6cm, soft, non-tender and attached to the skin (Figure 1).
He had a pulse of 80/min, regular and of a normal
volume. The blood pressure was 130/85 mmHg. The rest of
the cardiovascular examination was unrevealing.
Ophthalmological review revealed no significant abnormalities
in the eyes. Abdominal, central nervous system and respiratory
system examination were normal.
The chest X-ray was normal as was the abdominal
ultrasonography and CT scan of the abdomen. X-rays of the
left tibia and fibula (Figure 2) showed increased bone density,
more so the cortex, in the upper two thirds and rarification
in the lower third.
There was medial bowing of both the left tibia and fibula
in the mid-zone. These findings taken together, were reported
as being in keeping with fibrous dysplasia. Additional
investigations included a full blood count, urea/ creatinine/
electrolytes, liver enzymes and serum proteins, 24-hour
urinary VMA/metanephrines/normetanephrines and a blood
sugar, all of which were unrevealing. He was managed
conservatively.
Figure 1
(a) Massive enlargement of the left lower limb with
segmentation f the leg (Diffuse plexiform neurofibroma);
(b) Nodular plexiform neurofibroma
Figure 2
X-ray of the left tibia and fibula showing increased bone
density in the upper third and rarification in the lower
third
Case 2: A.N.N., a 45 year old female, first presented
to the Kenyatta National Hospital in July 2001. She presented
with a 6 year history of lower body swelling. The swelling
initially involved the feet and the ankle joints, but later
progressed to involve the knees, thighs and hips. There would
be periods when the swelling would decrease slightly. There
was associated “burning” pain at the waist, which radiated
down the legs. Seven months prior to admission she developed
a “blistering rash” over the affected part, which healed well.
This was followed by the development of nodules over the
area. There was accentuation of temperature sense in both
lower limbs. There was no history of local injury, local pain
or local warmth preceding the problem. There was also no
history of change in urine output, urine colour or frequency.
Enquiry was negative for orthopnoea, dyspnoea, easy
fatiguability, flushing and abnormal sweating. Sphincter
function and sensation remained normal. Vision was reported
to be normal, as were bowel habits.
She was functionally impaired, could not stand, walk,
or move her lower part of the body without assistance. She
was able to use her upper body and could feed herself. She
had been bed-bound for six months prior to presentation.
She had had four term pregnancies, the outcome being
three still-births and one living child with Erb’s palsy due
to a difficult delivery. She reported irregular menses at the
time, but was not using any contraceptives. Her social history
was unremarkable and there was no family history of similar
illnesses or of any other chronic illness.
In her past medical history, of significance was an
operation to excise a breast lesion, which was found to be
benign.On examination, she was a middle aged female in
good general condition, but looked gigantic. Findings of
significance included a photosensitive malar dermatitis(6
years, duration), two large coffee coloured skin lesions, one
near the umbilicus(8cm across) (Figure 3) and the other in
the right gluteal region (6cm across).
She was mildly pale. Her blood pressure was 140/90mm
Hg and weight 160kgs. On local examination of her waist
and lower body which was noted to be grossly enlarged
(Figure 4), it was noted that there was marked dimpling of
skin, resembling peau d’orange appearance. The legs appeared
segmented. Both legs and feet additionally had large sessile
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fleshy nodules. There was no tenderness or warmth over the
areas. Sensation was normal and capillary refill time was
normal. On further examination of the musculo-skeletal
system, a venous hum was auscultated in the coccygeal
region. Examination of the other systems was unrevealing.
Figure 3
Café-au-lait spot next to the umbilicus
Figure 4
Symmetrically arge, segmented lower limbs with sessile
neurofibromas
The investigations done included a full haemogram,
urea/creatinine/electrolytes, urinalysis, blood sugar, lipid
profile, coagulation profile, 24 hour urine for VMA/
metanephrines/catecholamines, growth hormone assay, HIV/
HbsAg, ELISA and a chest X-ray, all of which were
unrevealing. Echocardiography showed a dilated inferior vena
cava (3 cm), normal chambers and flows. Abdominal nd
pelvic ultrasound showed nothing significant except for a
mild hepatomegaly. X-rays of both legs showed an increase
in soft tissue mass with no bone or joint lesion. CT Scans
and MRI of the head, trunk and legs were not possible
because the patient could not fit into either machine. The
management was conservative with counseling playing a
greater ole.
DISCUSSION
Two contrasting cases of NF-1. The first case
clearly satisfied the diagnostic criteria for NF-1
developed by NIH Consensus Conference in 1987(3),
while the second did not. The NIH diagnostic criteria
ar  thought to be very reliable in distinguishing adults
with and without NF-1 on the basis of routine clinical
and ophthalmological examinations (5,6). In the first
case, there were cutaneous lesions, including numerous
large (greater than 1.5cm diameter) cafe`-au-lait spots,
axillary freckling and multiple nodular fibromas, not
to mention the plexiform neurofibroma, involving only
the left lower limb. In addition, the patient had bone
involvement in the form of fibrous dysplasia involving
the left tibia and fibula. In the second case, the two
large cafe`-au-lait spots and the symmetrical diffuse
plexiform neurofibromas involving the gluteal regions
and both lower limbs were not adequate criteria to
make a diagnosis of NF-1. It is, however, worth
mentioning that because of the large size of our second
patient, it was not possible to carry out comprehensive
investigations (particularly radiographic). This is relevant
considering the fact that NF-1 is a progressive
multisystem disorder that has cutaneous, ophthalmic,
central nervous system, vascular and osseous
manifestations(7), not to mention its strong association
with specific malignancies, including myelogenous
leukaemia(8), phaeochromocytoma(9), melanomas and
neuroblastomas(10). However, in situations where the
diagnosis of NF-1 with plexiform neurofibroma is not
clear, the differential diagnoses will include
lymphoedema, rterio-venus malformation at the
bifurcation of lower limb vessels, proteus syndrome
and multiple lipomatoses.
This autosomal dominant disease, whose gene has
been localised on chromosome 17q 11.2, affects between
1/2000 and 1/4500 people(2). This makes it not a rare
condition, an observation which has been made by our
own plastic surgeons (Audi and Aref, personal
communication). However, extensive, diffuse plexiform
neurofibromas are much rarer and to the best of our
knowledge, our second patient is the first report of
plexiform neurofibromatosis involving both lower limbs
in almost symmetrical fashion. We hypothesise that in
this patient, the disease involved the lumbar plexus,
spreading to affect the sciatic nerves in both lower
limbs. Half of all NF-1 cases are familial, and half are
caused by new mutations(2,11). It is, thus, not suprising
that we did not get any history of a similar illness in
the families of our two patients.
Th  treatment of such patients remains an enigma,
and in our patients was conservative, although the
mainstay of therapy for neurofibromas i surgery.
Medical therapies which are undergoing trial include
ketotifen, interferon alpha 2a, 13-cisretinoic acid
(isotretoin), inhibitors of angiogenesis, farnesyl protein
transferase inhibitors in and anti-sense
oligonucleotides(4).
In conclusion, we report on two cases of NF-1 the
management of which were challenging with one
presenting in a way that seems not to have been
described before.
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SHORT SCIENTIFIC LETTER
RUBELLA SEROPREVALENCE IN ADOLESCENT GIRLS IN THE EASTERN REGION OF TURKEY
Dear Sir,
The incidence of congenital rubella in a given
population is quite variable, depending on the number of
susceptible, the circulation of virus in the community, and
in recent times, the use of rubella vaccine(1). Although
rubella vaccination is routinely received in most western
countries it is not routinely provided in our country. In this
study, rubella seroprevalence was investigated in 400
adolescent girls in the Van region of Turkey to determine
rubella seroprevalence in adolescent girls in our region
(Eastern Region of Turkey).
The study includes 400 adolescent girls living in Van
region. None of the girls had rubella vaccination. The girls
aged between 11-13 years were accepted in the early
period of adolescence; those aged between 14-17 years in
the middle period of adolescence and those aged between
18-21 years in the late period of adolescence. Rubella-
specific IgG antibodies were screened by ELISA method.
For statistical analysis, Chi-square test was used. The
subjects age ranged from 11 to 21 years; 110 subjects were
in the early period of adolescence, 180 subjects were in the
middle period of adolescence and the other 110 subjects
were in the late period of adolescence. Antirubella IgG
was negative in 40 (10%) subjects and positive in the
remaining 360 (90%) subjects. The serum antirubella IgG
level was positive in 90 percent  (99/110) of subjects in the
group aged 11 to 13 years, in 87.9% (158,1180) of subjects
in the group aged 14 to 17 years, and in 93.7% (103/110)
of subjects in the group aged 18 to 21 years. There was not
a statistically significant difference in antirubella IG
positivity between the age groups.
The seropositivity rate in rubella has been reported
between 58.9-93% among women at reproductive age and
girls in the various regions of the world (1-5). In our study,
anti rubella IgG positivity was found to be 90% in
accordance with the literature. It was noted that
seropositivity rate increased with age in most studies
which were performed in order to determine whether or
not there was a relationship between seropositivity and
age (4-6).
However, in our study there was not a statistically
s gnificant difference between the age groups for antirubella
IgG positivity. In conclusion, we found that the lack
antibodies to rubella was 10% in adolescent girls in our
region. We suggest that rubella vaccine should routinely
be performed to girls in our country and in the world.
Yours sincerely
H. Ç ksen, MD, A. Ceylan, MD., N. Ceylan, MD.,
S. Arslan, MD; A.F. Öner, MD., E. Kirimi, MD., Yüzuncü
Yil University Medical Faculty, Van, Turkey
Request for reprints to: Dr. H. Caksen,
K. Kar bekir, C. Gölbasi, Erkam sitesi B Blok No. 3/7
VAN/TURKEY
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